PMID- 28178685 OWN - NLM STAT- MEDLINE DCOM- 20180406 LR - 20220410 IS - 1949-2553 (Electronic) IS - 1949-2553 (Linking) VI - 8 IP - 26 DP - 2017 Jun 27 TI - Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. PG - 42252-42261 LID - 10.18632/oncotarget.15036 [doi] AB - Currently, patients with radioiodine refractory differentiated thyroid cancer (RAIR-DTC) have limited treatment options. In this study, we aimed to assess the short-term efficacy and safety of apatinib in RAIR-DTC. Ten adult patients were prospectively enrolled to receive oral apatinib (750 mg q.d). The primary endpoints were change in serum thyroglobulin (Tg) concentration, disease control rate (DCR) and objective response rate (ORR) based on RECIST 1.1 criteria. The secondary endpoints included change in glucose metabolism, evaluated by maximum standard uptake value (SUVmax), and safety. As early as 2 weeks after apatinib treatment, the serum Tg concentration decreased by 21.0% in 8 patients available for detection without interference, and a further sharp decline by 81.4% compared with the baseline level occurred at 8 weeks post-treatment. The DCR and ORR were 100% (10/10) and 90% (9/10), respectively. The sum of tumor diameter shrank to 22.8+/-8.1 mm from 38.8+/-15.7 mm (P=0.001). Moreover, a significant decrease in SUVmax was observed from 6.53+/-5.14 to 2.56+/-1.67 and 2.45+/-1.48 at 4-week and 8-week time-points after treatment (P=0.032 and 0.020), respectively. The common grade 3 adverse events (AEs) included hand-foot-skin reaction (50%), hypertension (30%), and hypocalcemia (20%). No severe AE related to apatinib was observed during treatment. Hence, apatinib seems to be a promising therapeutic option for RAIR-DTC patients. Apart from RECIST 1.1 criteria, the biochemical marker (Tg) and glucose metabolism index (SUVmax) could be adopted in assessing the early response to TKI in RAIR-DTC. FAU - Lin, Yansong AU - Lin Y AD - Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing 100730, China. FAU - Wang, Chen AU - Wang C AD - Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing 100730, China. FAU - Gao, Wen AU - Gao W AD - Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266555, China. FAU - Cui, Ruixue AU - Cui R AD - Department of Nuclear Medicine, Peking Union Medical College Hospital, Beijing 100730, China. FAU - Liang, Jun AU - Liang J AD - Department of Oncology, Peking University International Hospital, Beijing 102206, China. LA - eng PT - Journal Article PL - United States TA - Oncotarget JT - Oncotarget JID - 101532965 RN - 0 (Antineoplastic Agents) RN - 0 (Iodine Radioisotopes) RN - 0 (Protein Kinase Inhibitors) RN - 0 (Pyridines) RN - 5S371K6132 (apatinib) SB - IM MH - Adult MH - Aged MH - Antineoplastic Agents/adverse effects/pharmacokinetics/*therapeutic use MH - Female MH - Humans MH - Iodine Radioisotopes/therapeutic use MH - Male MH - Middle Aged MH - Neoplasm Grading MH - Neoplasm Metastasis MH - Neoplasm Staging MH - Positron Emission Tomography Computed Tomography MH - Protein Kinase Inhibitors/adverse effects/pharmacokinetics/*therapeutic use MH - Pyridines/adverse effects/pharmacokinetics/*therapeutic use MH - Retreatment MH - Thyroid Neoplasms/diagnostic imaging/*drug therapy/*pathology MH - Tomography, X-Ray Computed MH - Treatment Outcome PMC - PMC5522064 OTO - NOTNLM OT - apatinib OT - maximum standard uptake value OT - radioiodine refractory differentiated thyroid cancer OT - safety OT - thyroglobulin COIS- CONFLICTS OF INTEREST The authors have no conflicts of interest to declare. EDAT- 2017/02/09 06:00 MHDA- 2018/04/07 06:00 PMCR- 2017/06/27 CRDT- 2017/02/09 06:00 PHST- 2016/09/26 00:00 [received] PHST- 2017/01/08 00:00 [accepted] PHST- 2017/02/09 06:00 [pubmed] PHST- 2018/04/07 06:00 [medline] PHST- 2017/02/09 06:00 [entrez] PHST- 2017/06/27 00:00 [pmc-release] AID - 15036 [pii] AID - 10.18632/oncotarget.15036 [doi] PST - ppublish SO - Oncotarget. 2017 Jun 27;8(26):42252-42261. doi: 10.18632/oncotarget.15036.